Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab in Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2023
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Frexalimab with Placebo (2 arms). Primary endpoint: Composite Confirmed Disability Progression at 36 months. Started Dec 2023; status: active, not recruiting.
02
Drugs
frexalimab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT06141486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141486.